RESEARCH TRIANGLE PARK, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointment of Mark Avagliano as Chief Business Officer. In this role, Mr. Avagliano will serve as a member of the G1 executive team and be responsible for leading the company’s global partnering and corporate development strategy and execution.

“Mark has experience executing a broad range of corporate development deals, including partnerships, joint ventures and strategic transactions. We are excited for him to lead our corporate development function, with the goal of bringing our investigational therapies to patients around the world while creating value for our shareholders,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer. “We are approaching important clinical, regulatory and commercial milestones across our pipeline, so this is an ideal time to add Mark’s expertise to our management team.”

“All three of G1’s therapeutic candidates have the potential to become new standards of care for women with breast cancer, including in the adjuvant setting, and trilaciclib may improve patient outcomes across a range of tumor types,” said Mr. Avagliano. “I’m excited about the opportunity to lead initiatives focused on making these therapies available globally to patients who need better treatment options.”

Prior to joining G1, Mr. Avagliano was Vice President, Corporate Development at Pfizer Inc., where he was responsible for the evaluation, planning and execution of significant corporate level transactions and oversaw the Mergers and Acquisitions, Transactions and Valuations, and Out-licensing groups. During his fifteen years at Pfizer, Mr. Avagliano successfully led the execution of numerous transactions, including acquisitions, divestitures, joint ventures, co-developments, co-promotions, product licenses, research collaborations, and public market separations. Mr. Avagliano has deep expertise in screening, evaluation, financial modeling, due diligence, contract negotiations, and deal closings. Prior to joining Pfizer in 2004, Mr. Avagliano held commercial and operational roles at Aventis Pharmaceuticals.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies. G1T48 is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 also has an active discovery program focused on cyclin-dependent kinase targets.

G1 is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.